Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.55 |
| ▸ | EED | O75530 | 11/20 | 0.55 |
| ▸ | RBBP4 | Q09028 | 11/20 | 0.55 |
| ▸ | SUZ12 | Q15022 | 11/20 | 0.55 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.55 |
| ▸ | AEBP2 | Q6ZN18 | 9/20 | 0.53 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279859 | 0.95 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL9280875 | 0.92 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL9887622 | 0.86 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL9277204 | 0.83 | EED (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL9281286 | 0.81 | EZH2 (0.50) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL9278330 | 0.80 | EZH2 (0.48) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL9281353 | 0.80 | EZH2 (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL9286474 | 0.79 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL9284810 | 0.78 | EZH2 (0.51) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL9281882 | 0.78 | EZH2 (0.69) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | claimed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | claimed |
| EP-2646020-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-10-09 | — | — | EP | claimed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | claimed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | claimed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765792-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2646020-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245016-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EED 3322/4885RBBP4 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.